Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Telix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.34 billion
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 312.25 million
Earnings per share -0.285
Dividend per share N/A
Year To Date Return -44.77%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Telix Pharmaceuticals Ltd (ASX: TLX)
Latest News

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

These were the best performing ASX 200 shares last week

These ASX 200 shares were on fire last week...

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

3 ASX shares destined for greatness: Firetrail

Stocks themselves have no memory, so even ones that have dropped violently this year can shoot back up if the…

Read more »

Two happy scientists analysing test results.
Healthcare Shares

10-baggers? Expert names 2 super-cheap biotech ASX shares

Biotech and health tech stocks have suffered greatly in recent months. But one fund manager is sticking by 2 particular…

Read more »

three young children weariing business suits, helmets and old fashioned aviator goggles wear aeroplane wings on their backs and jump with one arm outstretched into the air in an arid, sandy landscape.
Broker Notes

48% fall: Fund names 3 ASX shares to take off after heavy crash

Many non-mining stocks have been hammered this year, but that could mean there are some bargains waiting to skyrocket.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Share Fallers

Telix share price slips on quarterly update

Investors are still digesting the oncology company's results...

Read more »

a woman rugged up in a woolen hat and gloves with a thermometer in her mouth props her hand under her chin as she looks dejectedly at the camera,, as though she is miserable from feeling sick.
Healthcare Shares

ASX 200 healthcare shares were chronically ill last quarter. Take a look

They aren't exactly on the mend either.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Here’s why the Telix (ASX:TLX) share price surged 10% today

Here's what's boosted the biotech stock on Monday.

Read more »

Share Gainers

Why Block, Lake Resources, Nearmap, and Telix shares are racing higher

These ASX shares are racing higher on Tuesday...

Read more »

TLX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.

TLX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
20 May 2022 $4.28 $0.17 4.14% 1,001,634 $4.13 $4.35 $4.07
19 May 2022 $4.11 $-0.09 -2.14% 1,071,542 $4.00 $4.19 $4.00
18 May 2022 $4.20 $0.05 1.20% 964,889 $4.22 $4.26 $4.12
17 May 2022 $4.15 $0.21 5.33% 1,300,620 $3.90 $4.19 $3.86
16 May 2022 $3.94 $0.12 3.14% 905,277 $3.88 $3.98 $3.83
13 May 2022 $3.82 $0.27 7.61% 1,731,568 $3.61 $3.83 $3.59
12 May 2022 $3.55 $-0.44 -11.03% 2,399,535 $3.72 $3.79 $3.55
11 May 2022 $3.99 $0.14 3.64% 819,659 $3.90 $4.07 $3.76
10 May 2022 $3.85 $-0.09 -2.28% 1,280,797 $3.90 $3.93 $3.68
09 May 2022 $3.94 $-0.31 -7.29% 956,031 $4.16 $4.18 $3.86
06 May 2022 $4.25 $-0.02 -0.47% 580,187 $4.14 $4.30 $4.13
05 May 2022 $4.27 $0.21 5.17% 571,397 $4.16 $4.30 $4.13
04 May 2022 $4.06 $-0.18 -4.25% 677,696 $4.29 $4.30 $4.04
03 May 2022 $4.24 $-0.06 -1.40% 411,457 $4.23 $4.40 $4.23
02 May 2022 $4.30 $-0.31 -6.72% 590,504 $4.52 $4.52 $4.30
29 Apr 2022 $4.61 $0.39 9.24% 954,640 $4.28 $4.64 $4.27
28 Apr 2022 $4.22 $-0.11 -2.54% 876,816 $4.35 $4.43 $4.16
27 Apr 2022 $4.33 $0.00 0.00% 767,496 $4.29 $4.45 $4.26
26 Apr 2022 $4.33 $-0.11 -2.48% 901,587 $4.35 $4.37 $4.27
22 Apr 2022 $4.44 $-0.16 -3.48% 436,441 $4.54 $4.58 $4.44

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Apr 2022 Oliver Buck Buy 250 $1,092,500
On-market trade.
03 Feb 2022 Christian Behrenbruch Buy 400 $436,000
Exercise of options.
03 Feb 2022 Christian Behrenbruch Exercise 400 $436,000
Exercise of options.
27 Jan 2022 Andreas Kluge Sell 2 $15,400,000
As advised by the company. The Sell-Down reflects the first sale of shares by
Dr Behrenbruch or Dr Kluge since the
Company' s inception in December 2015
27 Jan 2022 Christian Behrenbruch Sell 2 $15,400,000
As advised by the company. The Sell-Down reflects the first sale of shares by
Dr Behrenbruch or Dr Kluge since the
Companys inception in December 2015.
29 Sep 2021 Mark Nelson Exercise 990 $841,500
Exercise of options.
29 Sep 2021 Mark Nelson Buy 990 $841,500
Exercise of options.
29 Sep 2021 Harry McCann Buy 990 $841,500
Exercise of options.
29 Sep 2021 Harry McCann Exercise 990 $841,500
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Harry Kevin McCann Non-Executive ChairmanNon-Executive Director Sep 2017
Mr McCann has board experience with some of Australia's companies. He is Chairman of China Matters and a member of Champions of Change, a ProChancellor of the University of Sydney, and a Trustee of the Sydney Opera House Trust. Previously, Kevin has been Chairman of Macquarie Group and Macquarie Bank Limited, Chairman of Origin Energy Limited, Healthscope Limited and ING Management Limited. Kevin practiced as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He is chair of the people, culture and a member of the risk committee.
Ms Jann E Skinner Non-Executive Director Jun 2018
Ms Skinner has experience in audit and accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She is an independent non-executive director of QBE Insurance Group Limited, where she also serves as Chair of the Audit Committee and Deputy Chair of the Risk & Capital Committee. She also serves as a Director of the Create Foundation Limited and HSBC Bank Australia Limited. She is Chair of the risk committee and a member of the people, culture and disclosure committee.
Dr Christian Peter Behrenbruch Chief Executive OfficerManaging Director Jan 2017
Dr Behrenbruch has over twenty years of healthcare entrepreneurship and executive leadership experience. He has previously served in a CEO or Executive Director capacity at Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. He is a former Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix) and was the former Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre).
Dr Andreas Kluge Non-Executive Director Jan 2017
Dr Kluge has over 20 years of clinical research and development experience, including as Founder, General Manager and Medical Director for ABX CRO, a full service CRO for Phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He is also Founder and was founding CEO of ABX GmbH, manufacturers of radiopharmaceutical precursors globally. Andreas is further Founder, General Manager and Medical Director for Therapeia, an early-stage development company in the field of neurooncology, which was acquired by Telix. Andreas has experience in the practice of Nuclear Medicine and radiochemistry, molecular imaging and the clinical development of novel radionuclide-based products and devices. He is the author of numerous patents and publications in the field of Nuclear Medicine, neurology, infection and immunology.
Mr Oliver Buck Non-Executive Director Jan 2017
Mr Buck has spent his professional career in a range of entrepreneurial and management positions in industrial companies. He has served as founder and Managing Director of range of companies in the fields of manufacturing, technology, demilitarisation, pharmaceuticals and information technologies. He is the co-founder of ITM Isotopen Technologien Munchen AG. Since 2012, he has acted as senior advisor to the CEO in a role that continues to support the ITM group as it has become a leader in next generation medical isotopes and theranostics. He is a member of the Risk, People and culture committee.
Dr Mark Alexander Nelson Non-Executive Director Sep 2017
Dr Nelson is Chairman and Co-Founder of the Caledonia Investments Group, and a Director of The Caledonia Foundation. He is Chairman of Art Exhibitions Australia, a Director of Kaldor Public Art Projects, Director of The Mindgardens Neuroscience Network, and serves as a Governor of the Florey Neurosciences Institute. Previously he was a Director of The Howard Florey Institute of Experimental Physiology and Medicine, and served on the Commercialisation Committee of the Florey Institute. He is a member of the Risk, People and culture committee.
Ms Tiffany Olson Non-Executive Director Mar 2022
Ms Olson has experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceutical sector. Her most recent executive role was with Cardinal Health, where she was President of Cardinal Health Nuclear & Precision Health Solutions overseeing Cardinal's radiopharmaceutical manufacturing and nuclear pharmacy network. Prior to her role at Cardinal Health, Ms Olson served as President of NaviMed and in executive roles at Eli Lilly and Roche, where she attained the position of President and CEO of Roche Diagnostics Corporation. Ms Olson currently serves as a Board member for Castle Biosciences; ERF, Education & Research Foundation for Nuclear Medicine & Molecular Imaging; and is on the Langham Logistics Advisory Board. She was named one of the "10 Best Women Leaders of 2020" by Industry Era and was the first woman to receive the Life Science Alley Luminary Award.
Ms Melanie Farris Chief Governance & Risk OfficerCompany Secretary Mar 2017
-
Jonathan Barlow Chief Business Development Officer
-
Douglas Cubbin Chief Financial Officer
-
Melanie Farris Chief Governance & Risk OfficerCompany Secretary
-
Colin Hayward Chief Medical Officer
-
Gabriel Liberatore Chief Operating Officer
-
Helen Hovenga Chief People Officer
-
Michael Wheatcroft Chief Scientist
-
Tracey Brown Global SVP Product Portfolio Management
-
Scott Law SVP Global Manufacturing Operations
-
Kyahn Williamson SVP Investor Relations and Corporate Communications
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 41,027,846 13.31%
J P Morgan Nominees Australia Pty Limited 25,203,406 8.18%
Elk River Holdings Pty Ltd 22,675,000 7.36%
Gnosis Verwaltungsgesellschaftm B H 22,675,000 7.36%
Grand Decade Developments Limited 20,947,181 6.80%
Citicorp Nominees Pty Limited 14,637,434 4.75%
National Nominees Limited 9,925,410 3.22%
UV Cap Gmbh & Co Kg 7,775,000 2.52%
The Oncidium Foundation 6,398,550 2.08%
Scintec Diagnostics Gmbh 4,312,151 1.40%
Ubs Nominees Pty Ltd 4,305,063 1.40%
BNP Paribas Nominees Pty Ltd 3,843,512 1.25%
BNP Paribas Nominees Pty Ltd Acf Clearstream 3,630,279 1.18%
BNP Paribas Noms Pty Ltd 3,268,729 1.06%
Man Holdings Pty Ltd 3,228,750 1.05%
Yelwac Pty Ltd 2,381,804 0.77%
HSBC Custody Nominees (Australia) Limited A/C 2 2,334,746 0.76%
Netwealth Investments Limited 2,184,202 0.71%
Pacific Custodians Pty Limited 2,115,000 0.69%
Jean Marc Le Doussal 2,010,000 0.65%
BNP Paribas Nominees Pty Ltd (i) 1,955,863 0.63%

Profile

since

Note